AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer’s Disease
AC Immune SA (ACIU)
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acimmune.com/en/investors
Company Research
Source: GlobeNewswire
Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the rate of cognitive decline vs. placebo Benefit of semorinemab on ADAS-Cog11 in all prespecified subgroups was consistent with the treatment effect in the overall cohort, regardless of disease severity, baseline Tau load, and ApoE carrier status Benefit on cognition was driven primarily by the memory domain subcomponent of ADAS-Cog11, a core feature of AD Further analyses evaluating semorinemab’s effects on cerebrospinal fluid (CSF) biomarkers are ongoing as is the open label portion of the study LAUSANNE, Switzerland, Nov. 10, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Genentech, a member of the Roche Group, presented the full topline data from Laur
Show less
Read more
Impact Snapshot
Event Time:
ACIU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACIU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
- Further weakness as AC Immune (NASDAQ:ACIU) drops 12% this week, taking three-year losses to 58% [Yahoo! Finance]Yahoo! Finance
- AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update [Yahoo! Finance]Yahoo! Finance
- AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate UpdateGlobeNewswire
- AC Immune Announces Upcoming Presentations at AD/PD™ 2024 [Yahoo! Finance]Yahoo! Finance
ACIU
Earnings
- 11/3/23 - Miss
ACIU
Sec Filings
- 3/14/24 - Form F-3
- 3/14/24 - Form 6-K
- 3/14/24 - Form 20-F
- ACIU's page on the SEC website